Onpattro
(Patisiran)ApprovedRNA therapy
Alnylam PharmaceuticalsOnpattro is a rna therapy that works as a TTR Sirna.[2] It is being used across 7 indications, with its most advanced program in Approved.[1]
Onpattro is one of 160 sirna programs targeting Liver Transplant. It is currently in Approved.
7
Indications
11
Total Trials
2
Active Trials
159
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Onpattro
Alnylam PharmaceuticalsApproved
Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Monoferric
PPharmacosmos A/S
Preclinical
Activase
RochePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Zemplar
AbbViePreclinical
Zoloft
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Amyloidosis5 trials
Cardiomyopathy2 trials
Polyneuropathy1 trial
Hereditary Transthyretin Amyloidosis1 trial
Regulatory
FDA Approval Timeline[4]
Aug 10, 2018
ONPATTRO
NDA NDA210922
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Patisiran. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- TTR Sirna[2]
- Modality
- RNA therapy[2]
- Highest Phase
- Approved[1]
- Company